A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GX-I7 in Healthy Volunteers
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Efineptakin alfa (Primary) ; Efineptakin alfa (Primary)
- Indications Breast cancer; Cervical intraepithelial neoplasia; Glioblastoma; Human papillomavirus infections; Leucopenia; Lymphoma; Skin cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Genexine
- 03 Apr 2019 Results (n=10) presented at the 110th Annual Meeting of the American Association for Cancer Research
- 21 Oct 2018 Status changed from active, no longer recruiting to completed.
- 01 Jun 2018 Planned number of patients changed from 40 to 30.